SUMMARY: Colorectal cancer (CRC) is the third most common cancer diagnosed in both men and women in the United States. The American Cancer Society estimates that approximately 158,850 new cases of CRC will be diagnosed in the United States in 2026 and about 55,230 patients will die of the disease.
BRAF is a very important intermediary of the RAS-RAF-MEK-ERK pathway. The BRAF V600E mutations results in constitutive activation of the MAP kinase pathway. Inhibiting BRAF can transiently reduce MAP kinase signaling. However, this can result in feedback upregulation of EGFR signaling pathway, which can then reactivate the MAP kinase pathway. This aberrant signaling can be blocked by dual inhibition of both BRAF and EGFR.
BRAF V600E mutations are found in approximately 8-10% of metastatic CRC and are associated with aggressive tumor biology, poor prognosis, and limited response to conventional first-line therapies. These patients tend to have aggressive disease with a higher rate of peritoneal metastasis and do not respond well to standard treatment intervention.
Encorafenib (BRAFTOVI®) is a BRAF inhibitor and has target binding characteristics that differ from other BRAF inhibitors such as Vemurafenib (ZELBORAF®) and Dabrafenib (TAFINLAR®), with a prolonged target dissociation half-life and higher potency. Cetuximab (ERBITUX®) is an anti EGFR (Epidermal Growth Factor Receptor) targeted monoclonal antibody.
Design of the BREAKWATER Study
BREAKWATER is a multicenter, open-label Phase III trial evaluating targeted treatment strategies for patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer. Cohort 1 and 2 evaluated Encorafenib plus Cetuximab with or without mFOLFOX6 chemotherapy and results demonstrated significant clinical efficacy, leading the FDA to grant full approval to the Encorafenib combination regimen for first-line mCRC. However, because both FOLFOX and FOLFIRI remain widely used chemotherapy backbones in metastatic colorectal cancer, an important unanswered question was whether similar benefits could be achieved using a FOLFIRI-based regimen.
To address this, investigators evaluated the combination of Encorafenib, Cetuximab, and FOLFIRI in Cohort 3 of the BREAKWATER trial. Cohort 3 enrolled 147 patients with measurable disease and an ECOG Performance Status of 0 or 1. Patients were randomized 1:1 to receive either Encorafenib plus Cetuximab and FOLFIRI or standard FOLFIRI with or without Bevacizumab. The Primary endpoint was Objective Response Rate (ORR) assessed by Blinded Independent Central Review (BICR), while Progression-Free Survival (PFS) served as the key Secondary endpoint. Overall Survival (OS) and safety were also evaluated. Baseline demographic and disease characteristics were well balanced between treatment arms.
Significant Improvements across Multiple Clinical Endpoints
Earlier analyses demonstrated a marked improvement in tumor response with the targeted combination, and the final analysis confirmed durable benefits across efficacy endpoints.
The addition of Encorafenib and Cetuximab to FOLFIRI reduced the risk of disease progression or death by 56% compared with standard chemotherapy (HR=0.44; P=0.0002). Median PFS nearly doubled, increasing from 8.3 months in the control arm to 15.2 months with the targeted regimen.
Overall Survival also improved substantially. Median OS had not yet been reached in the investigational arm at the time of analysis, compared with 20.3 months for the control group, corresponding to a 44% reduction in the risk of death (HR=0.56). The estimated 18-month OS rate reached 72% with the targeted combination versus 54.5% with standard therapy.
Objective responses remained consistently superior. The confirmed ORR was 64.4% with Encorafenib plus Cetuximab and FOLFIRI compared with 39.2% for chemotherapy alone, representing a statistically significant improvement.
Importantly, treatment benefit was observed consistently across all predefined patient subgroups, including age, sex, ECOG performance status, tumor sidedness, liver metastases, and extent of disease.
Durable Disease Control
Patients receiving the targeted regimen remained on treatment considerably longer than those receiving standard therapy. The median duration of treatment was 67.9 weeks with Encorafenib plus Cetuximab and FOLFIRI compared with 32.1 weeks in the control arm. At the January 2026 data cutoff, 38.4% of patients receiving the investigational regimen remained on treatment, compared with only 9.5% of patients receiving standard chemotherapy.
These findings suggest not only improved tumor control but also sustained clinical benefit over time.
Safety Profile Remains Consistent
The addition of targeted therapy did not introduce unexpected toxicities and no new safety signals emerged during longer follow-up. Treatment-emergent adverse events were consistent with the established safety profiles of Encorafenib, Cetuximab, and FOLFIRI. Although adverse events occurred in nearly all patients, the incidence of Grade 3 or 4 treatment-emergent adverse events was numerically lower with the targeted regimen (70.4%) than with standard chemotherapy (80.9%).
Regulatory Impact
The BREAKWATER program has rapidly influenced clinical practice. In December 2024, the FDA granted accelerated approval to Encorafenib plus Cetuximab with mFOLFOX6 for patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer. Following the positive results from Cohort 3, the FDA expanded approval in February 2026 to include Encorafenib plus Cetuximab combined with Fluorouracil-based chemotherapy, providing clinicians with the option of either mFOLFOX6 or FOLFIRI as chemotherapy backbones. This expanded indication increases treatment flexibility while preserving the benefits of precision-targeted therapy.
Clinical Implications
The findings from BREAKWATER Cohort 3 further strengthen the role of biomarker-directed therapy in the first-line treatment of BRAF V600E-mutant metastatic colorectal cancer. By demonstrating significant improvements in response rate, PFS, and OS with a FOLFIRI backbone, the study expands treatment flexibility beyond the previously established mFOLFOX6 regimen.
These results also underscore the critical role of early comprehensive molecular testing. Identifying a BRAF V600E mutation before initiation of first-line therapy enables patients to receive biomarker-directed treatment that significantly improves response rates, prolongs disease control, and extends survival compared with conventional chemotherapy alone.
The study supports Encorafenib plus Cetuximab and FOLFIRI as an additional standard-of-care option, enabling clinicians to tailor chemotherapy backbone selection according to individual patient characteristics and treatment goals.
Conclusion
The final analysis of BREAKWATER Cohort 3 establishes Encorafenib plus Cetuximab and FOLFIRI as an important new first-line standard-of-care option for patients with BRAF V600E-mutant metastatic colorectal cancer. Together with earlier BREAKWATER findings, these results expand first-line treatment options for this high-risk molecular subtype and further establish biomarker-driven therapy as the preferred approach for delivering personalized care.
BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC). Kopetz S, Tabernero J, Lorandi S, et al. J Clin Oncol. 2026;44(suppl 17):LBA3503.
